G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation.

[1]  N. Song,et al.  The association between MIF‐173 G>C polymorphism and prostate cancer in southern Chinese , 2009, Journal of surgical oncology.

[2]  M. Asaka,et al.  Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation , 2009, International journal of laboratory hematology.

[3]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[4]  D. Hanauer,et al.  CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. , 2007, Blood.

[5]  Annette Lee,et al.  Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence , 2007, Genes and Immunity.

[6]  A. Berrebi,et al.  IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival , 2007, Proceedings of the National Academy of Sciences.

[7]  G. Kuchel,et al.  Null mutation for Macrophage Migration Inhibitory Factor (MIF) is associated with less aggressive bladder cancer in mice , 2007, BMC Cancer.

[8]  M. Sykes,et al.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. , 2007, Blood.

[9]  Carlos Flores,et al.  Macrophage migration inhibitory factor in acute lung injury: expression, biomarker, and associations. , 2007, Translational research : the journal of laboratory and clinical medicine.

[10]  S. Brand,et al.  Macrophage migration inhibitory factor (MIF) −173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease , 2007, Inflammatory bowel diseases.

[11]  K. Iczkowski,et al.  Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells1 , 2006, The Journal of Immunology.

[12]  M. Imamura,et al.  Effect of macrophage migration inhibitory factor (MIF) on acute graft-versus-host disease in a murine model of allogeneic stem cell transplantation. , 2006, Transplant Immunology.

[13]  M. Asaka,et al.  Regulation of Toll-like receptor 4 expression in mouse colon by macrophage migration inhibitory factor , 2006, Histochemistry and Cell Biology.

[14]  R. Bucala,et al.  Macrophage migration inhibitory factor. , 2005, Critical care medicine.

[15]  R. Korngold,et al.  A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses , 2005, Nature Medicine.

[16]  G. Fingerle-Rowson,et al.  MIF loss impairs Myc-induced lymphomagenesis , 2005, Cell Death and Differentiation.

[17]  T. Hagemann,et al.  Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK1 , 2005, The Journal of Immunology.

[18]  Yuji Sato,et al.  Evidence of dual function of macrophage migration inhibitory factor relevant to tumor progression and regression. , 2005, International Journal of Molecular Medicine.

[19]  D. Jain,et al.  Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. , 2004, Blood.

[20]  D. Ray,et al.  Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. , 2004, The Journal of endocrinology.

[21]  G. Vogelsang,et al.  Chronic graft versus host disease , 2004, British journal of haematology.

[22]  C. Dinarello,et al.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Epplen,et al.  Complex genetic predisposition in adult and juvenile rheumatoid arthritis , 2004, BMC Genetics.

[24]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[25]  C. Miracco,et al.  Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis , 2003, Annals of the rheumatic diseases.

[26]  R. Bucala,et al.  Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[27]  M. Suematsu,et al.  Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction , 2003, Nature Immunology.

[28]  J. Crawford,et al.  T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.

[29]  E. Zeggini,et al.  Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. , 2002, Arthritis and rheumatism.

[30]  R. Liang,et al.  Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients , 2002, Bone Marrow Transplantation.

[31]  W. Thomson,et al.  Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. , 2002, The Journal of rheumatology.

[32]  N. Horiike,et al.  Macrophage migration inhibitory factor activates antigen‐presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis , 2002, Clinical and experimental immunology.

[33]  J. Ferrara,et al.  Acute graft-versus-host disease does not require alloantigen expression on host epithelium , 2002, Nature Medicine.

[34]  J. Bernhagen,et al.  Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. , 2002, Microbes and infection.

[35]  A. Thomson,et al.  Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. , 2001, Blood.

[36]  A. Dickinson,et al.  Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. , 2001, Blood.

[37]  W. Thomson,et al.  A novel 5′‐flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic‐onset juvenile idiopathic arthritis , 2001 .

[38]  M. V. D. van den Brink,et al.  Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. , 2001, Blood.

[39]  Y. Aizawa,et al.  Contribution of TNF-α and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation , 2000, Bone Marrow Transplantation.

[40]  R. Bucala,et al.  Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.

[41]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[42]  R. Bucala,et al.  An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma , 1999, Molecular medicine.

[43]  A. Satoskar,et al.  Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis , 1999, The Journal of experimental medicine.

[44]  G. Jackson,et al.  Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. , 1998, Blood.

[45]  R. Bucala,et al.  Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 1997, Nature Medicine.

[46]  C. Kozak,et al.  Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q11.2. , 1997, Genomics.

[47]  R. Bucala,et al.  An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Bernhagen,et al.  MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.

[49]  J. Bernhagen,et al.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor , 1994, The Journal of experimental medicine.

[50]  K. Tracey,et al.  MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.

[51]  Rachel L. Mistur,et al.  Graft-Versus-Host Disease , 2016 .

[52]  J. David,et al.  Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[54]  J. David.  Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[55]  B. Bloom,et al.  Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.

[56]  J. Loutit,et al.  Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.

[57]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[58]  T. Tahara,et al.  Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. , 2008, Oncology reports.